Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Chemotherapy in Advanced Esophageal Carcinoma (China Extension)
NCT03881111Phase 3Withdrawn
- Sponsor
- Merck & Co.
- Start
- Jan 2019
- Primary completion
- May 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in esophageal carcinoma, sponsored by Merck & Co.. Planned start Jan 2019; status: withdrawn.
02
Drugs
03
Conditions
esophageal carcinoma
Beyond the preview
Go deeper on NCT03881111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03881111.